More access to GLP-1s ≠ better obesity care.
Without proper clinical oversight, we’re seeing: • Inconsistent use • Short-term thinking for a chronic disease
Access is critical—but quality, continuity, and physician guidance matter just as much.
https://t.co/tJ1WaKOGZP
More access to GLP-1s ≠ better obesity care.
Without proper clinical oversight, we’re seeing:
• Inconsistent use
• Short-term thinking for a chronic disease
Access is critical—but quality, continuity, and physician guidance matter just as much.
https://t.co/tJ1WaKOGZP
Have your patients asked if the #Spatz3 balloon is safe during exercise? This video shows how it’s designed to be strong and secure - helping patients stay active and confident on their #weightlossjourney. #WeightManagement#PatientSafety
Have your patients asked if the #Spatz3 balloon is safe during exercise? This video shows how it’s designed to be strong and secure - helping patients stay active and confident on their #weightloss journey. #WeightManagement#PatientSafety
Have your patients asked if the #Spatz3 balloon is safe during exercise? This video shows how it’s designed to be strong and secure - helping patients stay active and confident on their weight loss journey.
#WeightManagement#PatientSafety
Have your patients asked if the #Spatz3 balloon is safe during exercise?
This video shows how it’s designed to be strong and secure - helping patients stay active and confident on their weight loss journey.
#WeightManagement#PatientSafety
Sustaining weight loss is often harder than achieving it.
The new @bmj_latest review reinforces the need for long-term, adaptable obesity care models - especially when pharmacologic therapy is interrupted.
Chronic disease requires durable strategy.
🔗 https://t.co/knStFoLnMG
Sustaining weight loss is often harder than achieving it. The new @bmj_latest review reinforces the need for long-term, adaptable obesity care models - especially when pharmacologic therapy is interrupted. Chronic disease requires durable strategy. https://t.co/knStFoLnMG
Sustaining weight loss is often harder than achieving it.
The new @bmj_latest review reinforces the need for long-term, adaptable obesity care models - especially when pharmacologic therapy is interrupted.
Chronic disease requires durable strategy.
https://t.co/knStFoLnMG
Watching these stories reminds us why we do this work. Obesity is complex, and every #journey is unique. The Spatz adjustable balloon supports sustainable weight loss - up to 34.7% of total body weight - adapting to each person’s journey. #Spatz3#ObesityCare
Watching these stories reminds us why we do this work. Obesity is complex, and every journey is unique. The Spatz adjustable balloon supports sustainable weight loss - up to 34.7% of total body weight - adapting to each person’s #journey. #Spatz3#ObesityCare
Watching these stories reminds us why we do this work. #Obesity is complex, and every journey is unique. The Spatz adjustable balloon supports sustainable weight loss - up to 34.7% of total body weight - adapting to each person’s journey. #Spatz3#ObesityCare
Watching these stories reminds us why we do this work. Obesity is complex, and every journey is unique. The Spatz adjustable balloon supports sustainable weight loss - up to 34.7% of total body weight - adapting to each person’s journey. #Spatz3#ObesityCare
As the world marked #WorldObesityDay earlier this week, 8 Billion Reasons To Act reminds us: obesity is complex, chronic, and global. Understanding, personalized care, and collaboration are key. Everyone has a role to play. #ObesityAwareness#HealthForAll
37% of insured adults report delaying or forgoing needed care due to cost. In obesity & metabolic care, continuity matters. Worth the read: https://t.co/yq0Wjux2gX @CareCredit
A recent @FDA letter flagged Novo Nordisk’s TV ad for oral Wegovy as “misleading,” citing unsupported claims beyond weight loss & unclear risk info. In #obesity care, credibility and evidence-based communication are essential - https://t.co/aHhD4MwAsl #Gastroenterology
A recent @FDA letter flagged Novo Nordisk’s TV ad for oral Wegovy as “misleading,” citing unsupported claims beyond #weightloss & unclear risk info. In obesity care, credibility and evidence-based communication are essential - https://t.co/aHhD4MwAsl #Gastroenterology
A recent @FDA letter flagged Novo Nordisk’s TV ad for oral Wegovy as “misleading,” citing unsupported claims beyond weight loss & unclear risk info. In obesity care, credibility and evidence-based communication are essential > https://t.co/aHhD4Mx8hT #Gastroenterology